Last reviewed · How we verify
nadroparine calcium
At a glance
| Generic name | nadroparine calcium |
|---|---|
| Sponsor | University Hospital, Geneva |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT） (PHASE4)
- Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT (NA)
- Safety of Anticoagulant Therapy After Endoscopic Treatment (PHASE4)
- Safety of Anticoagulant Therapy After Tissue Glue for Gastric Varices
- Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis (PHASE4)
- Immunosuppressant Regimens for Living Fetuses Study (NA)
- Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection (PHASE4)
- Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nadroparine calcium CI brief — competitive landscape report
- nadroparine calcium updates RSS · CI watch RSS
- University Hospital, Geneva portfolio CI